Tags : Nasal Powder

Eli Lilly’s Baqsimi (glucagon 3mg) Nasal Powder Receives FDA’s Approval

Shots: The FDA’s approval follows multiple studies with various age group evaluating baqsimi (glucagon, 3mg) nasal powder vs glucagon injection formulation in patients with diabetes aged 4yrs and older Collective study results demonstrated noninferiority data to glucagon injection formulation in raising blood glucose level after insulin-induced hypoglycemia, 100% patients reach treatment success  i.e, increase in […]Read More